Cargando…

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON

Detalles Bibliográficos
Autores principales:	Nasr, Lewis, Diab, Saada, Yehia, Intissar, Nasr, Fadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430360/ http://dx.doi.org/10.1097/01.HS9.0000974408.84720.7f

Ejemplares similares

PB1986: FIRST-LINE TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN A REAL-WORLD DATA SETTING IN LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1812: CO-MUTATION PROFILE IN A REAL-LIFE COHORT OF ACUTE MYELOID LEUKEMIA (AML)
por: Piras, Giovanna, et al.
Publicado: (2023)

PB1896: WHOLE EXOME SEQUENCING IDENTIFIES A NOVEL TRANSCRIPTION FACTOR ASSOCIATED WITH FATAL DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA
por: Iqbal, Z., et al.
Publicado: (2022)

PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE
por: Serin, I., et al.
Publicado: (2022)

PB1788: A SCREENING OF DONATED CHEMICAL PROBES TO IDENTIFY NOVEL THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA (AML) IN CHILDHOOD
por: Laszig, Stephanie, et al.
Publicado: (2023)

PB1852: COMPARISON OF CLINICAL CHARACTERISTICS OF ADULT CHILEAN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), ACCORDING TO THEIR HEALTH CARE SYSTEM: ANALYSIS WITHIN THE FRAMEWORK OF THE PTHEMA AML REGISTRY
por: Romero, Monica, et al.
Publicado: (2023)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
por: Brysting, Josephine, et al.
Publicado: (2023)

PB1898: FIVE-YEAR REAL-WORLD DATA ON ACUTE MYELOID LEUKEMIA: RETROSPECTIVE STUDY FROM PUBLIC HEALTH CENTER IN BRAZIL
por: Feistauer, Felipe, et al.
Publicado: (2023)

PB2498: A PHASE 1 STUDY OF WU-NK-101 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Cashen, Amanda, et al.
Publicado: (2023)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

PB2219: A REAL-WORLD EXPERIENCE WITH HEALTHCARE RESOURCE UTILIZATION PATTERNS AND RELATED COSTS IN PATIENTS WITH SICKLE CELL DISEASE IN NORTH LEBANON
por: Inati, A., et al.
Publicado: (2022)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
por: Wei, Wenjian, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

PB1734: SURVIVAL OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN ECUADOR. AN ANALYSIS OF THE REAL WORLD
por: Sabando, Brenner, et al.
Publicado: (2023)

PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
por: Martini, Gianluca, et al.
Publicado: (2023)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

PB1977: EVALUATION OF ANTIBODY RESPONSES AMONG FIVE DIFFERENT SARS-COV-2 VACCINES IN CHRONIC MYELOID LEUKEMIA PATIENTS – A REAL-WORLD STUDY
por: Toreli, Ana Carolina, et al.
Publicado: (2023)

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Daver, N. G., et al.
Publicado: (2022)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
por: Mo, Qianxing, et al.
Publicado: (2023)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
por: Ajtić, Olivera Mitrović, et al.
Publicado: (2023)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
por: Urbano, M., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
por: Pantic, N., et al.
Publicado: (2022)

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
por: Gordienko, Alla, et al.
Publicado: (2023)

PB1863: VENETOCLAX AND HYPOMETHYLATING AGENT BASED OUTPATIENT AML INDUCTION- COST-EFFECTIVE METHOD FOR LMICS-REAL WORLD DATA FROM A TERTIARY CARE CENTER
por: Chauhan, Priyanka, et al.
Publicado: (2023)

PB1801: MYCN IS REQUIRED FOR MAINTAINING AN ONCOGENIC CHARACTERISTICS OF LEUKEMIA CELLS IN ACUTE MYELOID LEUKEMIA
por: Huang, Nanfang, et al.
Publicado: (2023)

PB1800: CLINICAL CHARACTERISTICS AND MUTATION LANDSCAPE OF TRISOMY AML
por: Lam, Stephen S Y, et al.
Publicado: (2023)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

PB1867: ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 – REAL-LIFE EXPERIENCE IN THE REDEFINITION OF EUROPEAN LEUKEMIANET RISK CLASSIFICATION
por: Gomes, Rita S, et al.
Publicado: (2023)

PB1764: SEGMENTATION AND CLASSIFICATION OF BONE MARROW CELLS FROM MULTI-PRECISION NUMERIZATION OF BONE MARROW SMEARS (BMS) FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) USING AI TECHNIQUES
por: Bennis, Achraf, et al.
Publicado: (2023)

PB1772: IN-VITRO APOPTOTIC EFFECT OF NATURALLY OCCURRING COMPOUNDS, PIPERINE AND ASCORBIC ACID ON ACUTE MYELOID LEUKAEMAI (AML) CELL LINE.
por: Aljohani, R., et al.
Publicado: (2022)

PB1795: BIO-INSPIRED NANOMEDICINE FOR TARGETED ACUTE MYELOID LEUKEMIA IMMUNOTHERAPY
por: Wang, X., et al.
Publicado: (2022)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hfgu9ge0619dlg5qhp0d4q3dig